Systematic Reviews and Meta-analysesProgression of Elderly Onset Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Population-Based Cohort Studies
Section snippets
Methods
This systematic review followed the Preferred Reporting Items for Systematic reviews and Meta-Analysis standards and followed an a priori protocol.
Results
We identified 5204 unique studies using our search strategy, and after screening titles and abstracts, 51 full texts were reviewed. From this, 9 studies representing 7 unique population-based cohort studies were included in our synthesis.12, 13, 14, 15, 16, 17, 18, 19, 20 The study selection flowchart is shown in Figure 1.
Study characteristics are summarized in Table 1. Of the 7 cohorts, 6 were based in Europe and 1 in Canada. Each study compared a cohort of EO IBD patients vs 1 or more cohorts
Discussion
In this systematic review of population-based observational studies on EO IBD, we made several key observations regarding EO IBD vs AO IBD. First, we observed that risk of surgery, hospitalization, and disease progression is similar between EO IBD and AO IBD at a population level. Surgery carries a high risk in older patients; approximately 10% experience serious complications within the first 30 days, and 4% of patients die. Second, although the cumulative use of corticosteroids is high (and
CRediT Authorship Contributions
Jacob J. Rozich (Conceptualization: Supporting; Data curation: Lead; Formal analysis: Supporting; Writing – original draft: Supporting); Parambir S. Dulai (Conceptualization: Supporting; Formal analysis: Supporting; Writing – review & editing: Equal); Mathurin Fumery (Conceptualization: Supporting; Formal analysis: Supporting; Writing – review & editing: Supporting); William J. Sandborn (Conceptualization: Supporting; Writing – review & editing: Supporting); Siddharth Singh, MD
References (30)
- et al.
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
Lancet
(2018) - et al.
Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review
Gastroenterology
(2012) - et al.
Understanding and preventing the global increase of inflammatory bowel disease
Gastroenterology
(2017) - et al.
The burden of inflammatory bowel disease in Europe
J Crohns Colitis
(2013) - et al.
Past and future burden of inflammatory bowel diseases based on modeling of population-based data
Gastroenterology
(2019) - et al.
Incidence and treatment of patients diagnosed with inflammatory bowel diseases at 60 years or older in Sweden
Gastroenterology
(2018) - et al.
IBD in the elderly population: results from a population-based study in Western Hungary, 1977-2008
J Crohns Colitis
(2011) - et al.
Impact of age at diagnosis on natural history of patients with elderly-onset ulcerative colitis: a French population-based study
Dig Liver Dis
(2018) - et al.
The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States
Clin Gastroenterol Hepatol
(2007) - et al.
Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis
Clin Gastroenterol Hepatol
(2019)
Epidemiology of inflammatory bowel diseases from west to east
J Dig Dis
Report: economic implications of inflammatory bowel disease and its management
Am J Manag Care
Characterization of inflammatory bowel disease in elderly patients: a review of epidemiology, current practices and outcomes of current management strategies
Can J Gastroenterol Hepatol
Clinical implications of ageing for the management of IBD
Nat Rev Gastroenterol Hepatol
Systematic review and meta-analysis: phenotype and clinical outcomes of older-onset inflammatory bowel disease
J Crohns Colitis
Cited by (0)
Conflicts of interest These authors disclose the following: Parambir S. Dulai has received research support from Takeda, Pfizer, AbbVie, Janssen, Polymedco, ALPCO, Buhlmann, and Prometheus, and consulting fees from Takeda, Pfizer, AbbVie, and Janssen; Mathurin Fumery has received honoraria from AbbVie, MSD, Takeda, Janssen, Pfizer, Ferring, Celgene, Gilead, and Boehringer; William J. Sandborn has received research grants from Atlantic Healthcare Limited, Amgen, Genentech, Gilead Sciences, AbbVie, Janssen, Takeda, Lilly, Celgene/Receptos, consulting fees from AbbVie, Allergan, Amgen, Arena Pharmaceuticals, Avexegen Therapeutics, BeiGene, Boehringer Ingelheim, Celgene, Celltrion, Conatus, Cosmo, Escalier Biosciences, Ferring, Forbion, Genentech, Gilead Sciences, Gossamer Bio, Incyte, Janssen, Kyowa Kirin Pharmaceutical Research, Landos Biopharma, Lilly, Oppilan Pharma, Otsuka, Prizer, Precision IBD, Progenity, Prometheus Laboratories, Reistone, Ritter Pharmaceuticals, Robarts Clinical Trials (owned by Health Academic Research Trust), Series Therapeutics, Shire, Sienna Biopharmaceuticals, Sigmoid Biotechnologies, Sterna Biologicals, Sublimity Therapeutics, Takeda, Theravance Biopharma, Tigenix, Tillotts Pharma, UCB Pharma, Ventyx Biosciences, Vimalan Biosciences, Vivelix Pharmaceuticals, and stock or stock options from BeiGene, Escalier Biosciences, Gossamer Bio, Oppilan Pharma, Precision IBD, Progenity, Ritter Pharmaceuticals, Ventyx Biosciences, Vimalan Biosciences; and Siddharth Singh has received research grant support from AbbVie, has served as a consultant for AbbVie, Takeda, and AMAG Pharmaceuticals, and has received honorarium from Pfizer for ad hoc grant review. The remaining author discloses no conflicts.
Funding Research reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney Diseases grant K23DK117058 (S.S.) and P30 DK120515 (W.J.S.), by an American Gastroenterological Association Research Scholar Award (P.S.D.), by the American College of Gastroenterology Junior Faculty Development Award the Crohn’s and the Colitis Foundation Career Development Award 404614 and the IOIBD Operating Grant (S.S.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.